Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Dow
Boehringer Ingelheim
Moodys
Express Scripts
Mallinckrodt
AstraZeneca

Last Updated: May 26, 2022

INBRIJA Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

Which patents cover Inbrija, and when can generic versions of Inbrija launch?

Inbrija is a drug marketed by Acorda and is included in one NDA. There are ten patents protecting this drug.

This drug has one hundred patent family members in twenty-two countries.

The generic ingredient in INBRIJA is levodopa. There are eighteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the levodopa profile page.

DrugPatentWatch® Generic Entry Outlook for Inbrija

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be November 16, 2032. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Sign up for a Free Trial

Summary for INBRIJA
Drug patent expirations by year for INBRIJA
Drug Prices for INBRIJA

See drug prices for INBRIJA

DrugPatentWatch® Estimated Generic Entry Opportunity Date for INBRIJA
Generic Entry Date for INBRIJA*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
POWDER;INHALATION

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Anatomical Therapeutic Chemical (ATC) Classes for INBRIJA

US Patents and Regulatory Information for INBRIJA

INBRIJA is protected by ten US patents.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of INBRIJA is See Plans and Pricing.

This potential generic entry date is based on patent See Plans and Pricing.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting INBRIJA

Particulate compositions for pulmonary delivery
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Particulate compositions for pulmonary delivery
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Pulmonary delivery for levodopa
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: INTERMITTENT TREATMENT OF OFF EPISODES IN PATIENTS WITH PARKINSON'S DISEASE TREATED WITH CARBIDOPA/LEVODOPA BY INHALATION OF LEVODOPA POWDER PARTICLES

Capsules containing high doses of levodopa for pulmonary use
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Pulmonary delivery for levodopa
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: INTERMITTENT TREATMENT OF OFF EPISODES IN PATIENTS WITH PARKINSON'S DISEASE TREATED WITH CARBIDOPA/LEVODOPA BY INHALATION OF LEVODOPA POWDER PARTICLES

Capsules containing high doses of levodopa for pulmonary use
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Capsules containing high doses of levodopa for pulmonary use
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Pulmonary delivery for levodopa
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Capsules containing high doses of levodopa for pulmonary use
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Pulmonary delivery for levodopa
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: INTERMITTENT TREATMENT OF OFF EPISODES IN PATIENTS WITH PARKINSON'S DISEASE TREATED WITH CARBIDOPA/LEVODOPA BY INHALATION OF LEVODOPA POWDER PARTICLES

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Acorda INBRIJA levodopa POWDER;INHALATION 209184-001 Dec 21, 2018 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Acorda INBRIJA levodopa POWDER;INHALATION 209184-001 Dec 21, 2018 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Acorda INBRIJA levodopa POWDER;INHALATION 209184-001 Dec 21, 2018 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Acorda INBRIJA levodopa POWDER;INHALATION 209184-001 Dec 21, 2018 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Acorda INBRIJA levodopa POWDER;INHALATION 209184-001 Dec 21, 2018 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Acorda INBRIJA levodopa POWDER;INHALATION 209184-001 Dec 21, 2018 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Acorda INBRIJA levodopa POWDER;INHALATION 209184-001 Dec 21, 2018 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for INBRIJA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Acorda INBRIJA levodopa POWDER;INHALATION 209184-001 Dec 21, 2018 See Plans and Pricing See Plans and Pricing
Acorda INBRIJA levodopa POWDER;INHALATION 209184-001 Dec 21, 2018 See Plans and Pricing See Plans and Pricing
Acorda INBRIJA levodopa POWDER;INHALATION 209184-001 Dec 21, 2018 See Plans and Pricing See Plans and Pricing
Acorda INBRIJA levodopa POWDER;INHALATION 209184-001 Dec 21, 2018 See Plans and Pricing See Plans and Pricing
Acorda INBRIJA levodopa POWDER;INHALATION 209184-001 Dec 21, 2018 See Plans and Pricing See Plans and Pricing
Acorda INBRIJA levodopa POWDER;INHALATION 209184-001 Dec 21, 2018 See Plans and Pricing See Plans and Pricing
Acorda INBRIJA levodopa POWDER;INHALATION 209184-001 Dec 21, 2018 See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for INBRIJA

When does loss-of-exclusivity occur for INBRIJA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Patent: 13342246
Estimated Expiration: See Plans and Pricing

Patent: 13342247
Estimated Expiration: See Plans and Pricing

Patent: 13342248
Estimated Expiration: See Plans and Pricing

Patent: 17279626
Estimated Expiration: See Plans and Pricing

Patent: 18204674
Estimated Expiration: See Plans and Pricing

Patent: 18222983
Estimated Expiration: See Plans and Pricing

Brazil

Patent: 2015010601
Estimated Expiration: See Plans and Pricing

Canada

Patent: 90451
Estimated Expiration: See Plans and Pricing

Patent: 90454
Estimated Expiration: See Plans and Pricing

Patent: 90459
Estimated Expiration: See Plans and Pricing

China

Patent: 4918607
Estimated Expiration: See Plans and Pricing

Patent: 5120843
Estimated Expiration: See Plans and Pricing

Patent: 9106697
Estimated Expiration: See Plans and Pricing

Patent: 0833539
Estimated Expiration: See Plans and Pricing

Denmark

Patent: 16821
Estimated Expiration: See Plans and Pricing

European Patent Office

Patent: 16821
Estimated Expiration: See Plans and Pricing

Patent: 16826
Estimated Expiration: See Plans and Pricing

Patent: 25611
Estimated Expiration: See Plans and Pricing

Patent: 15679
Estimated Expiration: See Plans and Pricing

Patent: 57301
Estimated Expiration: See Plans and Pricing

Hong Kong

Patent: 12884
Estimated Expiration: See Plans and Pricing

Patent: 13186
Estimated Expiration: See Plans and Pricing

Patent: 13187
Estimated Expiration: See Plans and Pricing

Patent: 13535
Estimated Expiration: See Plans and Pricing

Patent: 14957
Estimated Expiration: See Plans and Pricing

Japan

Patent: 47786
Estimated Expiration: See Plans and Pricing

Patent: 48501
Estimated Expiration: See Plans and Pricing

Patent: 69808
Estimated Expiration: See Plans and Pricing

Patent: 21629
Estimated Expiration: See Plans and Pricing

Patent: 36834
Estimated Expiration: See Plans and Pricing

Patent: 15536197
Estimated Expiration: See Plans and Pricing

Patent: 15536988
Estimated Expiration: See Plans and Pricing

Patent: 15536989
Estimated Expiration: See Plans and Pricing

Patent: 18150355
Estimated Expiration: See Plans and Pricing

Patent: 18162258
Estimated Expiration: See Plans and Pricing

Patent: 19213867
Estimated Expiration: See Plans and Pricing

Mexico

Patent: 1008
Estimated Expiration: See Plans and Pricing

Patent: 15005767
Estimated Expiration: See Plans and Pricing

Patent: 15005768
Estimated Expiration: See Plans and Pricing

New Zealand

Patent: 8682
Estimated Expiration: See Plans and Pricing

Patent: 8684
Estimated Expiration: See Plans and Pricing

Patent: 3459
Estimated Expiration: See Plans and Pricing

Patent: 7376
Estimated Expiration: See Plans and Pricing

Patent: 7378
Estimated Expiration: See Plans and Pricing

Poland

Patent: 16821
Estimated Expiration: See Plans and Pricing

Portugal

Patent: 16821
Estimated Expiration: See Plans and Pricing

Russian Federation

Patent: 70987
Estimated Expiration: See Plans and Pricing

Patent: 76093
Estimated Expiration: See Plans and Pricing

Patent: 15121091
Estimated Expiration: See Plans and Pricing

Patent: 15121092
Estimated Expiration: See Plans and Pricing

Patent: 18144622
Estimated Expiration: See Plans and Pricing

Singapore

Patent: 201706465X
Estimated Expiration: See Plans and Pricing

Patent: 201707103S
Estimated Expiration: See Plans and Pricing

Patent: 202109328Q
Estimated Expiration: See Plans and Pricing

Patent: 201503543P
Estimated Expiration: See Plans and Pricing

Patent: 201503547T
Estimated Expiration: See Plans and Pricing

South Africa

Patent: 1504058
Estimated Expiration: See Plans and Pricing

Patent: 1504060
Estimated Expiration: See Plans and Pricing

South Korea

Patent: 2257164
Estimated Expiration: See Plans and Pricing

Patent: 2337781
Estimated Expiration: See Plans and Pricing

Patent: 150108816
Estimated Expiration: See Plans and Pricing

Patent: 150110480
Estimated Expiration: See Plans and Pricing

Patent: 210062730
Estimated Expiration: See Plans and Pricing

Patent: 210152020
Estimated Expiration: See Plans and Pricing

Spain

Patent: 44153
Estimated Expiration: See Plans and Pricing

Patent: 80271
Estimated Expiration: See Plans and Pricing

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering INBRIJA around the world.

Country Patent Number Title Estimated Expiration
Lithuania 2630954 See Plans and Pricing
European Patent Office 2916826 POUDRES PULMONAIRES DE DENSITÉ ULTRA BASSE (ULTRA LOW DENSITY PULMONARY POWDERS) See Plans and Pricing
China 105120843 Ultra low density pulmonary powders See Plans and Pricing
Israel 158357 INHALATION DEVICE See Plans and Pricing
Israel 153281 See Plans and Pricing
Hong Kong 1213186 用於肺部使用的高劑量左旋多巴膠囊 (HIGH DOSE LEVODOPA CAPSULES FOR PULMONARY USE) See Plans and Pricing
Canada 2465675 COMPOSITIONS PARTICULAIRES AMELIOREES DESTINEES A ETRE ADMINISTREES PAR VOIE PULMONAIRE (IMPROVED PARTICULATE COMPOSITIONS FOR PULMONARY DELIVERY) See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for INBRIJA

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1613296 92782 Luxembourg See Plans and Pricing PRODUCT NAME: SAFINAMIDE A UTILISER EN COMBINAISON AVEC LEVODOPA/PDI, ET EVENTUELLEMENT AVEC D'AUTRES MEDICAMENTS PD , POUR LE TRAITEMENT DE LA MALADIE DE PARKINSON; FIRST REGISTRATION DATE: 20150224
1613296 CR 2015 00042 Denmark See Plans and Pricing PRODUCT NAME: KOMBINATION AF SAFINAMID, HERUNDER SAFINAMID METHANSULFONAT, OG LEVODOPA/PDI; REG. NO/DATE: EU/1/14/984/001-010 20150226
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Mallinckrodt
Dow
Express Scripts
McKinsey
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.